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Abstract 
AN ADAPTIVE DOSE FINDING DESIGN (DOSEFIND) USING A NONLINEAR 
DOSE RESPONSE MODEL 
By James Michael Davenport, PhD 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2007 
Major Director: R. K. Elswick 
Interim Department Chair, Biostatistics 
First-in-man (FIM) Phase I clinical trials are part of the critical path in the development of 
a new compound entity (NCE). Since FIM clinical trials are the first time that an NCE is 
dosed in human subjects, the designs used in these trials are unique and geared toward 
patient safety. We develop a method for obtaining the desired response using an adaptive 
non-linear approach. This method is applicable for studies in which MTD, NOEL, 
NOAEL, PK, PD effects or other such endpoints are evaluated to determine the desired 
dose. The method has application whenever a measurable PD marker is an indicator of 
potential efficacy and could be particularly useful for dose finding studies. The advantages 
in the adaptive non-linear methodology is that the actual range of dose response and lowest 
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non-effective dose levels are more quickly and accurately determined using fewer subjects 
than typically needed for a conventional early phase clinical trial. Using the nonlinear 
logistic model, we demonstrate, with simulations, that the DOSEFIND approach has better 
asymptotic relative efficiency than a fixed-dose approach. Further, we demonstrate that, 
on average, this method is consistent in reproducing .the target dose, that it has very little 
bias. This is an indicator of reproducibility of the method, showing that the long-run 
average error is quite small. Additionally, DOSEFIND is more cost effective because the 
sample size needed to obtain the desired target dose is much smaller than that needed in the 
fixed dose approach. 





















































































































































































